Topics

Clinical Trials About "Safety Study Of Intravenous Levetiracetam" RSS

05:18 EDT 29th March 2020 | BioPortfolio

We list hundreds of Clinical Trials about "Safety Study Of Intravenous Levetiracetam" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Safety Study Of Intravenous Levetiracetam" on BioPortfolio

We have published hundreds of Safety Study Of Intravenous Levetiracetam news stories on BioPortfolio along with dozens of Safety Study Of Intravenous Levetiracetam Clinical Trials and PubMed Articles about Safety Study Of Intravenous Levetiracetam for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Safety Study Of Intravenous Levetiracetam Companies in our database. You can also find out about relevant Safety Study Of Intravenous Levetiracetam Drugs and Medications on this site too.

Showing "Safety Study Intravenous Levetiracetam" Clinical Trials 1–25 of 31,000+

Extremely Relevant

Safety Study Of Intravenous Levetiracetam

The test article for this study is levetiracetam (Keppra, which is commercially available. Keppra is indicated for use as adjunctive therapy in the treatment of partial onset seizure disorders in patients age four years and above. An intravenous dosage form of levetiracetam is available for patients who are unable to take the oral form. UCB has conducted pharmacokinetic studies in normal volunteers and one safety study in epileptic patients using IV levetiracetam. These stu...


IV Levetiracetam for the Treatment of Neonatal Seizures: a Pharmacokinetic and Preliminary Efficacy and Safety Study

The purpose of this study is to determine the correct dosing for intravenous levetiracetam in term new born babies with seizures. In addition information on safety and efficacy will be collected. This new anticonvulsant drug is a promising treatment for seizures in newborns.

Efficacy of Intravenous Levetiracetam in Neonatal Seizures

A new anticonvulsant, levetiracetam will be studied to treat seizures in newborn infants. Current treatments for the brain damaging complication of neonatal seizures are unsatisfactory. Monitoring for seizure detection will be tested at five (5) US sites and one (1) international site using the internet.


Study of Antiepileptic Drug in Generalised Convulsive Status Epileptics

Compare the efficiency of the association, first line, the intravenous levetiracetam and the intravenous clonazepam, in that of a monotherapy of clonazepam intravenous in the pre-hospital treatment of tonicoclonic generalised status epileptics.

Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures

The hypothesis is that a loading dose of 20 mg/kg and a maintenance dose of 5 mg/kg of Levetiracetam is going to be safe and effective in the treatment of seizures in neonates.

Relevant

Safety and Tolerability Study of Levetiracetam to Treat Patients With Status Epilepticus

The purpose of this study is to determine whether levetiracetam is safe and well tolerated by patients while suffering a status epilepticus. Levetiracetam is added to the standard treatment of patients with this disease.

Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery

The purpose of this study is to determine the feasibility, efficacy and safety of intravenous and oral antiepileptic treatment with levetiracetam in patients with primary brain tumors and symptomatic epilepsy in the period of neurosurgical intervention.

A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy

The open-label study to allow pediatric patients who have participated in prior Levetiracetam (Keppra®) studies to continue their treatment with adequate monitoring and standardized follow-up care until Levetiracetam (Keppra®) is approved for use in children or until the completion of the development program for pediatrics.

Levetiracetam for Treatment of Pain Associated With Fibromyalgia

The purpose of this study is to assess the safety and effectiveness of levetiracetam in reducing the pain of fibromyalgia when compared to placebo. Levetiracetam, an anti-seizure drug, is currently FDA-approved and marketed for use in patients with seizures. Levetiracetam may relieve pain by reducing abnormal activity in the nervous system. A placebo is an inactive substance.

A Study of Levetiracetam in Japanese Pediatric Patients With Generalized Tonic-clonic Seizures

To evaluate the efficacy and safety of Levetiracetam dry syrup at doses up to 60 mg/kg/day or 3000 mg/day used as adjunctive therapy in Japanese pediatric patients aged ≥4 to

Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).

For ethical reasons to give opportunity for adult subjects (≥16 or 18 years) suffering from newly diagnosed epilepsy who completed the therapeutic confirmatory, open-label trial N01175 (NCT00175903) conducted with levetiracetam in monotherapy and who benefited from the treatment, to receive treatment with levetiracetam until the monotherapy indication for levetiracetam is granted in Europe. To continue to assess safety of levetiracetam as per adverse event reporting and obse...

Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy

Keppra injection is approved in the US as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. The objective of the current study is to assess the pharmacokinetics, safety and tolerability of this formulation in children aged 1 month to 4 years.

Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy

Community based study assessing safety and efficacy of levetiracetam in partial onset seizures. The optimal dose in daily clinical practice will be used.

Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.

An open-label follow-up trial assessing the long term safety of levetiracetam as per adverse events reporting.

Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease

The primary purpose of this study is to characterize the acute anti-dyskinetic properties of intravenous levetiracetam in Parkinson's disease patients who have been optimized on antiparkinsonian medication. The secondary objective is to study the effect of intravenous LEV on additional motor and cognitive symptoms of PD.

Bridging Study of L059 (Levetiracetam) in Patients With Epilepsy by Double Blind Method

Double-blind, randomized, placebo-controlled, multi center trial to evaluate the efficacy and safety of levetiracetam as adjunctive treatment in adult Japanese epileptic subjects with partial onset seizures.

A 16 Week Study Evaluating Levetiracetam in the Treatment of Post Herpetic Neuralgia (PHN)

16 week trial assessing the efficacy, safety, and tolerability of levetiracetam compared with placebo in the treatment of postherpetic neuralgia.

A Bioequivalence Study of Levetiracetam Versus Keppra

The purpose of this study is to assess the bioequivalence of Levetiracetam versus Keppra administered under fasting conditions to healthy adult subjects.

Pharmacokinetic Study of Levetiracetam in Epileptic Pediatric Subjects Ranging in Age From 1 Month to Less Than 4 Years Old

The primary purpose of this study was to document the pharmacokinetic parameters of both levetiracetam and its metabolite, ucb L057, after a single dose of 20 mg/kg of levetiracetam in epileptic pediatric subjects, aged 1 month to less than 4 years.

A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures

This study is planned to evaluate the safety and efficacy of L059 (levetiracetam) in long-term administration in patients who completed N01020 [NCT00160165] or N01221 [NCT00280696].

Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fasting Conditions

The objective of this study was to prove the bioequivalence of Levetiracetam 750 mg Tablets under fasted conditions

Bioequivalency Study of Levetiracetam 1g Under Fasted Conditions

The objective of this study was to prove the bioequivalence of Levetiracetam 1000 mg Tablets under fasted conditions

A Safety and Efficacy Follow-up Study With Levetiracetam in Children (4-17 Years Old) Suffering From Absence Seizures

This long-term open label follow-up trial gave pediatric subjects suffering from typical absences in CAE or JAE the opportunity to continue levetiracetam treatment after participation in the pilot study (study N162) or the double-blind study (study N163). Safety and efficacy data were obtained.

Bioequivalency Study of Levetiracetam 1g Tablets Under Fed Conditions

The objective of this study was to prove the bioequivalence of Levetiracetam 1000 mg Tablets under fed conditions

Bioequivalence Study of Levetiracetam Tablets, 750 mg of Dr. Reddy's Under Fed Conditions

The purpose of this study is to compare the single-dose relative bioavailability study of Levetiracetam Tablets 750 mg with Keppra® 750 mg Tablets under fed conditions.


More From BioPortfolio on "Safety Study Of Intravenous Levetiracetam"

Quick Search